Literature DB >> 16772768

Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents.

Aron D Mosnaim1, Vasant V Ranade, Marion E Wolf, Javier Puente, M Antonieta Valenzuela.   

Abstract

The chemical structure of phenothiazine provides a most valuable molecular template for the development of agents able to interact with a wide variety of biological processes. Synthetic phenothiazines (with aliphatic, methylpiperazine, piperazine-ethanol, piperazine-ethyl, or piperidine side-chain) and/or phenothiazine-derived agents e.g., thioxanthenes, benzepines, imonostilbenes, tricyclic antidepressants, dimetothiazine, and cyproheptadine have been effective in the treatment of a number of medical conditions with widely different etiology. These include various currently clinically used drugs for their significant antihistamic, antipsychotic, anticholinergic (antiparkinson), antipruritic, and/or antiemetic properties. They are also employed, although to a minor extent, as antidepressants, antispasmodics, analgesics, and antiarrhythemics. Some of these agents are also useful as anti-inflammatory, coronary vasodilator, radioprotective, sedative, antitussive, and skeletal muscle-relaxing medication. Still, others show different degrees of effectiveness as antibacterials, anthelmintics, antimalarials, or local anesthetics; a few are valuable in the control of acute migraine attacks and intractable hiccough. Adding to the seemingly ever-expanding therapeutic use of phenothiazine derivatives, a number of "old" and newly synthesized compounds e.g., "half-mustard-type" and benzo[alpha]phenothiazines, appear to be helpful as multidrug resistance modifiers, a property of particular importance in cancer chemotherapy. Some phenothiazines inhibit human plasmatic leucine-enkephalin aminopeptidase(s), enzymes known to regulate the turnover rate of a wide range of bioactive substances. These findings could lead to the design of new therapeutic treatment modalities for conditions such as Alzeimer's and Creutzfeldt-Jakob disease. Hopefully, this work will help to the rational design of new and improved pharmacological approaches based on a better understanding of the correlation between chemical structure, pharmacodynamic properties, and pharmacological activity of various phenothiazines and phenothiazine-derived classes of drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772768     DOI: 10.1097/01.mjt.0000212897.20458.63

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  15 in total

1.  In vitro methionine5-enkephalin degradation kinetics by human brain preparations.

Authors:  Aron David Mosnaim; Tao D Nguyen; Robert Tse; Javier Puente; Pastor Couceyro; Marion E Wolf
Journal:  Neurochem Res       Date:  2007-08-04       Impact factor: 3.996

2.  Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

Authors:  Tara L Spires-Jones; Taylor Friedman; Rose Pitstick; Manuela Polydoro; Allyson Roe; George A Carlson; Bradley T Hyman
Journal:  Neurosci Lett       Date:  2014-01-21       Impact factor: 3.046

3.  Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.

Authors:  John C O'Leary; Qingyou Li; Paul Marinec; Laura J Blair; Erin E Congdon; Amelia G Johnson; Umesh K Jinwal; John Koren; Jeffrey R Jones; Clara Kraft; Melinda Peters; Jose F Abisambra; Karen E Duff; Edwin J Weeber; Jason E Gestwicki; Chad A Dickey
Journal:  Mol Neurodegener       Date:  2010-11-01       Impact factor: 14.195

4.  A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates.

Authors:  Andrea L Johnstone; Gillian W Reierson; Robin P Smith; Jeffrey L Goldberg; Vance P Lemmon; John L Bixby
Journal:  Mol Cell Neurosci       Date:  2012-05-03       Impact factor: 4.314

Review 5.  The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics.

Authors:  Susanne M Pritchard; Philip J Dolan; Alisa Vitkus; Gail V W Johnson
Journal:  J Cell Mol Med       Date:  2011-08       Impact factor: 5.310

6.  Synthesis, spectroscopic characterization, and anticancer activity of new 10-substituted 1,6-diazaphenothiazines.

Authors:  Beata Morak-Młodawska; Krystian Pluta; Małgorzata Latocha; Małgorzata Jeleń
Journal:  Med Chem Res       Date:  2016-08-04       Impact factor: 1.965

Review 7.  Biological correlates of migraine and cluster headaches: an overview of their potential use in diagnosis and treatment.

Authors:  Aron D Mosnaim; Javier Puente; Marion E Wolf
Journal:  Pragmat Obs Res       Date:  2010-12-03

8.  Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents.

Authors:  Beata Morak-Młodawska; Krystian Pluta; Małgorzata Latocha; Małgorzata Jeleń; Dariusz Kuśmierz
Journal:  Molecules       Date:  2019-11-30       Impact factor: 4.411

9.  New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents.

Authors:  Mayank Kumar Sharma; Jatin Machhi; Prashant Murumkar; Mange Ram Yadav
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

10.  The immunosuppressive activities of newly synthesized azaphenothiazines in human and mouse models.

Authors:  Michał Zimecki; Jolanta Artym; Maja Kocieba; Krystian Pluta; Beata Morak-Młodawska; Małgorzata Jeleń
Journal:  Cell Mol Biol Lett       Date:  2009-06-25       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.